Table 3.
Omadacycline History
| Characteristic | No. (%) |
|---|---|
| Duration of treatment, mo | |
| Median | 8 |
| Range | 0.25–33 |
| Interquartile range | 4–15 |
| Dose of omadacycline | |
| 150 mg daily | 4 (3.4) |
| 300 mg daily | 112 (95.7) |
| Unspecified | 1 (<1) |
| Rationale for use of omadacyclinea | |
| Initial therapy | 13 (11.1) |
| Transition from intravenous therapy | 54 (46.2) |
| Addition to regimen for treatment of refractory disease | 37 (31.6) |
| Intolerance to other NTM therapy | 28 (23.9) |
| Patients who discontinued therapy during study period | 60 (51.3) |
| Reason for discontinuation, No. (% of total treated, N = 117) | |
| Completion of planned therapy | 20 (17.1) |
| Adverse event or intolerance | 23 (19.7) |
| Cost | 7 (6.0) |
| Death (not related to NTM infection or treatment) | 4 (3.4) |
| Otherb | 6 (5.1) |
Data are presented as No. (%) unless otherwise indicated. Data are inclusive of those who stopped treatment as well as those who were on active treatment at the time of data extraction.
Abbreviation: NTM, nontuberculous mycobacteria.
a
Some patients with multiple/overlapping indications for omadacycline therapy.
b
Included the following: pregnancy (n = 1), growth of Mycobacterium avium complex (n = 1), resumption of intravenous therapy (n = 1), unknown (n = 2), discontinued due to development of inducible macrolide resistance so as to avoid antimicrobial monotherapy (n = 1).